Company
Every published round Roche Group took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies Roche Group has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| No portfolio companies recorded yet. | ||||
Fund closes reported for Roche Group, as distinct from the investments it has made.
Companies Roche Group has backed that another company then bought. An exit for the holding, not a deal Roche Group did.
| Company | Bought by | Kind | Announced | Price |
|---|---|---|---|---|
| No portfolio company of Roche Group is recorded as having been acquired. | ||||
Companies Roche Group acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Company | Kind | Announced | Price | Sources |
|---|---|---|---|---|
| Spark Therapeutics | Acquisition | 2019 | - | Brandon Capital portfolio, Brandon BioCatalyst portfolio |
| Name | Role | Sources |
|---|---|---|
| Dr Steve Burnell | Executive (former) | Business News Australia, Brandon Capital portfolio, Brandon BioCatalyst portfolio |
Stories naming Roche Group. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Sanofi is buying Vicebio for up to US$1.6 billion in the biggest-ever exit of Australian university IP, with UQ keeping equity; the article also recalls the Inflazome and Spinifex sales and Vicebio's Medicxi seed.
Profile of Australian biotech Recce Pharmaceuticals, whose synthetic antibiotic candidates target drug-resistant infections, covering its leadership team, FDA designation, clinical trial progress and a government underwriting of its R&D rebate.
Sydney diagnostics developer SpeeDx banked $26 million for American expansion, with $5 million from Andrew Forrest's new fund Tenmile and follow-on support from Platinum and Northpond.
Also SmartCompany
Biotech Aravax has received a US$20 million Series B commitment from Brandon Capital and Tenmile to advance its peanut allergy therapy PVX108 into Phase 2 trials.
Also Brandon Capital portfolio·Startup Daily·Startup News (WA)·Techboard·Startup Daily
Sydney clinical trials platform HealthMatch raised a $10 million Series C led by Folklore Ventures with Square Peg participating, after laying off half its staff in June; funds will support rehiring and US expansion.
Also SmartCompany·Techboard
Cancer biotech Amaroq Therapeutics appointed four experts to its advisory board as it moves toward clinical trials; the New Zealand company's backers include Brandon Capital, which reports $14m invested to date.
Digital health firm Perx Health has raised a $3m seed round, led by AirTree Ventures, to support its move into the American market; co-founder and chief executive Scott Taylor has shifted to Chicago.
Eye-disease drug developer Azura Ophthalmics has appointed healthcare biotech veteran Steven Altschuler, a Ziff Capital Partners managing director and Spark Therapeutics co-founder, as chair of its board.
Australian pharmaceutical developer Hatchtech appoints Tim Waugh, a former Roche divisional vice president, as chief executive officer to lead development and commercialisation of its head lice treatment DeOvo and establish a United States presence.
Biotech Proacta's release: its Phase I cancer-drug trial is underway, and Alta Partners' new funding tops the Series A up to $12M alongside lead backer GBS Ventures; Alta's David Mack joins the board.
Folklore Ventures founder story recalling its seed backing of Manuri Gunawardena's clinical trial matching startup HealthMatch, plus follow-ons in its Series A and December 2020 Series B alongside Square Peg.